JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Xencor Inc

Closed

SectorHealthcare

13.21 7.22

Overview

Share price change

24h

Current

Min

13.04

Max

13.38

Key metrics

By Trading Economics

Income

18M

-31M

Sales

11M

44M

Profit margin

-70.687

Employees

250

EBITDA

17M

-20M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+85.09% upside

Dividends

By Dow Jones

Next Earnings

4 Nov 2025

Market Stats

By TradingEconomics

Market Cap

509M

1.1B

Previous open

5.99

Previous close

13.21

News Sentiment

By Acuity

50%

50%

147 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Xencor Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Oct 2025, 18:41 UTC

Earnings

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 Oct 2025, 18:31 UTC

Earnings

Correction to Procter & Gamble to Focus on Innovation

24 Oct 2025, 16:25 UTC

Major Market Movers

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 Oct 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 Oct 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 Oct 2025, 21:07 UTC

Earnings

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 Oct 2025, 20:58 UTC

Earnings

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 Oct 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 Oct 2025, 20:40 UTC

Earnings

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 Oct 2025, 20:24 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 Oct 2025, 20:23 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 Oct 2025, 20:13 UTC

Earnings

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 Oct 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 Oct 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 Oct 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 Oct 2025, 19:33 UTC

Earnings

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 Oct 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 Oct 2025, 18:52 UTC

Earnings

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 Oct 2025, 18:41 UTC

Earnings

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 Oct 2025, 18:03 UTC

Earnings

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 Oct 2025, 18:02 UTC

Earnings

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 Oct 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 Oct 2025, 16:57 UTC

Earnings

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 Oct 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 Oct 2025, 16:44 UTC

Market Talk
Earnings

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 Oct 2025, 16:39 UTC

Market Talk
Earnings

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 Oct 2025, 16:33 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 Oct 2025, 16:23 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 Oct 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24 Oct 2025, 16:07 UTC

Earnings

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer Comparison

Price change

Xencor Inc Forecast

Price Target

By TipRanks

85.09% upside

12 Months Forecast

Average 24.45 USD  85.09%

High 40 USD

Low 6 USD

Based on 13 Wall Street analysts offering 12 month price targets forXencor Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

10

Buy

1

Hold

2

Sell

Technical Score

By Trading Central

7.87 / 10.84Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

147 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat